Phase Forward Introduces Phase Forward™ IRT 5.0 Interactive Response Technology Solution
News Oct 26, 2009
Phase Forward has announced a major new release of its Interactive Response Technology (IRT) solution, Phase Forward™ IRT 5.0. Based on best-in-breed technology gained in the company’s September 2008 acquisition of Clarix, Phase Forward IRT 5.0 gives managers direct control over clinical supply management and helps to provide assurance of supply availability at randomization.
Phase Forward IRT also offers a new integrated drug forecasting module for advanced global clinical trial supply management and a new, enhanced user interface to streamline navigation and consolidate workflow.
“Phase Forward IRT 5.0 is a major step forward in helping customers leverage the power of IRT technology to improve efficiency within clinical trial supply management and planning, a crucial factor in every trial’s success,” said Steve Rosenberg, senior vice president of products and services, Phase Forward. “This release is a key component of our integrated clinical research suite for end-to-end clinical trial management.”
The Phase Forward IRT 5.0 release introduces a new “smart system intelligence” feature that puts clinical supply managers in control, helping them effectively respond to sudden increases in new subjects at any point in the trial. On the basis of user-defined variables, the application will either automatically generate a supply order or notify the supply manager of a potential stock-out, ensuring that subject enrollment is not compromised by lack of study supplies.
The new integrated drug forecasting module gives managers pre-study planning tools to optimize trial supply strategies. During live trials the application links to trial data on demand, enabling managers to compare planning assumptions and forecasts with actual trial data, update supply demand assumptions as needed and modify manufacturing schedules to respond to new projections.
New user interface and dashboard views provide at-a-glance access to critical information, visual status alerts and filtering capabilities to guide users intuitively through tasks, consolidating workflow and helping to ensure that the most pertinent information stays paramount. The release also provides multilingual capabilities, including Japanese, to enable use across the global trial community.
Together, Phase Forward’s IRT and InForm™ GTM electronic data capture (EDC) solutions offer users a tightly integrated solution with a single, unified interface and seamless workflow, providing the total cost of ownership and single point of contact benefits inherent in a single vendor solution.
The Phase Forward IRT 5.0 solution and the optional forecasting module are immediately available.
Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line TreatmentNews
The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.READ MORE
Diabetes Drug Could Be Re-purposed to Help End Transplant RejectionNews
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs.READ MORE
Study Shows Cancer Patients Are Choosing Less Severe Side Effects Over Treatment EfficacyNews
When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious adverse events according to a new study.READ MORE